EPIPAGE2: EPIPAGE 2 - 10-year Follow-up (RECONAI PROJECT)

Sponsor
Institut National de la Santé Et de la Recherche Médicale, France (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05243901
Collaborator
(none)
4,000
5.9

Study Details

Study Description

Brief Summary

Epipage 2 (Epidemiological study on small gestational ages) is a prospective population-based national cohort implemented to better understand the short, mid and long term future of premature children.

This study was launched on 28 March 2011 by the researchers of the EPOPé team (Perinatal, Obstetric and Pediatric Epidemiology Research) of the Epidemiology and Biostatistics Research Centre (INSERM U1153), in collaboration with the Inserm 1027 Unit (Epidemiology and Analysis in Public Health: risks, chronic diseases and handicaps) and medical teams of public health and research in 25 French regions.

The study focuses on children born before 35 weeks of amenorrhea.

3 follow-up steps for children included in the cohort have already been completed at 1, 2 and 5 and a half years of age. Currently, nearly 4,000 children are still eligible for follow-up.

Since the children are 9 years old, the follow-up steps are shared with those set up in another birth cohort, the Elfe cohort (Étude Longitudinale Française depuis l'Enfance, (www.elfe-france.fr) ), as part of the RE-CO-NAI project.

The RE-CO-NAI project is a research platform on cohorts of children followed since birth in order to be able to study in a global and multidisciplinary way the major issues of the health, development and socialization of children.

This RE-CO-NAI project was funded by the EQUIPEX 2011 call for projects as part of future investments.

This protocol, which is part of the RECONAI project, concerns the fully shared follow-up phase, proposed in the 10th year for the children of the two cohorts.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The objectives of this new follow-up phase are to study:
    • the relationships between prematurity, early growth and cardiometabolic disorders

    • the relationship between parenting educational skills and children's quality of life

    • the factors influencing children's puberty development

    • the factors influencing the child's fitness and motor skills

    Study design:

    The 10 and a half year follow-up phase is a Category 2 Human Person Research (IHRP 2).

    Study population The study population corresponds to all children who have participated in the Epipage 2 cohort since birth and whose parents did not wish to stop follow-up in the study. In total, nearly 4,000 children will be invited to participate in this new follow-up phase.

    Methodology:
    This follow-up phase will take place in 3 steps:
    1. A telephone interview with one of the parents living regularly with the child. Parents will be asked to answer several questions concerning their family situation, the school (homework, school support), the health, sleep and nutrition of the child, the general health and mental health of the parent interviewed, the employment situation, the living conditions and educational practices of the family.

    2. The home visit of the families of an investigator who will propose to the families several activities:

    • An interview with the child about his relations with his siblings, his comrades, his involvement in domestic activities and an estimate of his quality of life;

    • A physical examination measuring some of the child's health parameters and including tests of physical fitness and motor skills;

    • A test of the child's cognitive abilities;

    • A parent self-administered questionnaire including a parent's cognitive abilities test (self-administered);

    1. Biological samples from the child (blood, urine, saliva hair)

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    4000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    EPIPAGE2 Cohort Study Follow up at Ten and a Half Years
    Anticipated Study Start Date :
    Feb 1, 2022
    Anticipated Primary Completion Date :
    Aug 1, 2022
    Anticipated Study Completion Date :
    Aug 1, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Relationships between prematurity, early growth and cardiometabolic disorders [10 years and a half]

      Different cardiometabolic parameters will be studied (90th percentile waist for age and sex, 90th percentile systolic or diastolic pressure for age and sex)

    2. Relationship between parenting educational skills and children's quality of life [10 years and a half]

      VSPA scale (Adolescent Experience and Perceived Health)

    3. Factors influencing children's puberty development [10 years and a half]

      Tanner stage

    4. Factors influencing the child's fitness and motor skills [10 years and a half]

      Children's Endurance and Motor Ability Test Results upper or equal to 75th percentile of distribution for sex

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    10 Years to 11 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Children initially included in the Epipage 2 study,

    • Not lost to follow up (i.e. having participated in at least one of the Epipage 2 surveys since the age of 1 year),

    • Neither parent has expressed a definitive refusal to participate in the follow-up study.

    Exclusion Criteria:
    • Refusal of the investigation by one of the two parents or holders of parental authority,

    • Residence abroad

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Institut National de la Santé Et de la Recherche Médicale, France

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Institut National de la Santé Et de la Recherche Médicale, France
    ClinicalTrials.gov Identifier:
    NCT05243901
    Other Study ID Numbers:
    • C20-68
    First Posted:
    Feb 17, 2022
    Last Update Posted:
    Feb 17, 2022
    Last Verified:
    Feb 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 17, 2022